Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DBTX |
---|---|---|
09:32 ET | 162 | 4.3 |
09:38 ET | 127 | 4.2016 |
09:41 ET | 100 | 4.4 |
10:03 ET | 400 | 4.37 |
10:08 ET | 200 | 4.25 |
10:14 ET | 200 | 4.25 |
10:35 ET | 266 | 4.25 |
10:55 ET | 100 | 4.275 |
11:22 ET | 266 | 4.25 |
11:36 ET | 400 | 4.28 |
11:42 ET | 630 | 4.25 |
11:45 ET | 5103 | 4.26 |
12:16 ET | 200 | 4.39 |
12:41 ET | 900 | 4.39 |
12:43 ET | 200 | 4.36 |
12:45 ET | 100 | 4.38 |
12:50 ET | 900 | 4.3873 |
12:52 ET | 1572 | 4.32 |
01:03 ET | 100 | 4.3202 |
01:06 ET | 300 | 4.32 |
01:30 ET | 200 | 4.35 |
01:32 ET | 200 | 4.35 |
02:06 ET | 100 | 4.31 |
02:18 ET | 875 | 4.33 |
02:20 ET | 240 | 4.31 |
02:22 ET | 500 | 4.3 |
02:29 ET | 300 | 4.32 |
03:03 ET | 100 | 4.355 |
03:25 ET | 188 | 4.36 |
03:38 ET | 1300 | 4.32 |
03:41 ET | 1817 | 4.27 |
03:45 ET | 200 | 4.27 |
03:48 ET | 200 | 4.31 |
03:50 ET | 100 | 4.3 |
03:52 ET | 500 | 4.305 |
03:57 ET | 100 | 4.335 |
03:59 ET | 1221 | 4.33 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Decibel Therapeutics Inc | 107.1M | -2.0x | --- |
aTyr Pharma Inc | 104.6M | -2.0x | --- |
Dare Bioscience Inc | 104.2M | -2.7x | --- |
Rezolute Inc | 101.4M | -1.0x | --- |
Anebulo Pharmaceuticals Inc | 97.8M | -2.7x | --- |
NuCana PLC | 80.9M | -1.8x | --- |
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $107.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.21 |
Book Value | $5.68 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.